Federico Sturzenegger, Argentina's Minister of Deregulation and State Transformation, issued a detailed statement on social media after the National Agri-food Health and Quality Service (Senasa) approved a Brazilian foot-and-mouth disease vaccine imported by Tecnovax. Sturzenegger described this development as 'the end of an unnecessary battle' that had persisted for two years, emphasizing the thorough approval process that the vaccine underwent. He cited an article from La Nacion to highlight the government's perspective regarding vaccine affordability and accessibility.

In his comments, Sturzenegger addressed criticisms aimed at Biogénesis-Bagó, the leading supplier of locally produced foot-and-mouth disease vaccines in Argentina. The government had raised concerns over Biogénesis-Bagó's pricing, which was reportedly higher than that of similar vaccines available in the region. The approval of the Brazilian vaccine by Senasa marks a significant step in diversifying the supply of this critical immunization, potentially benefiting farmers and livestock owners.

The implications of this development are multifaceted, as it not only reflects a shift in policy regarding vaccine sourcing but also indicates increased scrutiny on local producers regarding pricing practices. As the government aims to ensure that livestock vaccines are both affordable and accessible, the approval of the Tecnovax-imported vaccine could influence future regulations and the competitive landscape of veterinary pharmaceuticals in Argentina.